# Tango Therapeutics, Inc.: financial statements, quarterly

TNGX · Nasdaq · CIK 1819133 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tngx.md) · [Financials](/companies/tngx/financials.md) · [Filings](/companies/tngx/filings.md) · [Insiders](/companies/tngx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tngx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.7](/filings/0000950170-24-121818.md) | [5.4 d](/filings/0001193125-26-092518.md) | [6.5](/filings/0000950170-25-068549.md) | [19.9](/filings/0000950170-25-102392.md) | [11.6](/filings/0001193125-25-263680.md) | [4.1 d](/filings/0001193125-26-092518.md) | [5.4](/filings/0001193125-26-221656.md) | [3.2](/filings/0001193125-26-343424.md) | [53.8](/filings/0001193125-25-263680.md) | [0.0 d](/filings/0001193125-26-092518.md) | [0.0](/filings/0001193125-26-221656.md) | [0.0](/filings/0001193125-26-343424.md) |
| Research and development | $m | [27.1](/filings/0000950170-24-121818.md) | [31.3 d](/filings/0001193125-26-092518.md) | [38.1](/filings/0000950170-25-068549.md) | [38.7](/filings/0000950170-25-102392.md) | [33.3](/filings/0001193125-25-263680.md) | [33.9 d](/filings/0001193125-26-092518.md) | [36.4](/filings/0001193125-26-221656.md) | [32.8](/filings/0001193125-26-343424.md) | [30.8](/filings/0001193125-25-263680.md) | [32.1 d](/filings/0001193125-26-092518.md) | [33.5](/filings/0001193125-26-221656.md) | [37.2](/filings/0001193125-26-343424.md) |
| Operating income | $m | [(25.6)](/filings/0000950170-24-121818.md) | [(35.0) d](/filings/0001193125-26-092518.md) | [(42.3)](/filings/0000950170-25-068549.md) | [(29.6)](/filings/0000950170-25-102392.md) | [(32.9)](/filings/0001193125-25-263680.md) | [(40.9) d](/filings/0001193125-26-092518.md) | [(42.5)](/filings/0001193125-26-221656.md) | [(41.0)](/filings/0001193125-26-343424.md) | [14.1](/filings/0001193125-25-263680.md) | [(41.9) d](/filings/0001193125-26-092518.md) | [(48.8)](/filings/0001193125-26-221656.md) | [(59.8)](/filings/0001193125-26-343424.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-121818.md) | [0.0 d](/filings/0001193125-26-092518.md) | [0.0](/filings/0000950170-25-068549.md) | [0.1](/filings/0000950170-25-102392.md) | [0.1](/filings/0001193125-25-263680.md) | [0.0 d](/filings/0001193125-26-092518.md) | [0.0](/filings/0001193125-26-221656.md) | [0.0](/filings/0001193125-26-343424.md) | [(0.0)](/filings/0001193125-25-263680.md) | [(0.1) d](/filings/0001193125-26-092518.md) | [0.0](/filings/0001193125-26-221656.md) | [0.0](/filings/0001193125-26-343424.md) |
| Net income | $m | [(22.3)](/filings/0000950170-24-121818.md) | [(30.8) d](/filings/0001193125-26-092518.md) | [(37.9)](/filings/0001193125-25-263680.md) | [(25.6)](/filings/0001193125-25-263680.md) | [(29.2)](/filings/0001193125-25-263680.md) | [(37.7) d](/filings/0001193125-26-092518.md) | [(39.9)](/filings/0001193125-26-343424.md) | [(38.9)](/filings/0001193125-26-343424.md) | [15.9](/filings/0001193125-25-263680.md) | [(38.7) d](/filings/0001193125-26-092518.md) | [(45.5)](/filings/0001193125-26-343424.md) | [(55.3)](/filings/0001193125-26-343424.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0000950170-24-121818.md) | not reported | [(0.35)](/filings/0000950170-25-068549.md) | [(0.24)](/filings/0000950170-25-102392.md) | [(0.27)](/filings/0001193125-25-263680.md) | not reported | [(0.36)](/filings/0001193125-26-221656.md) | [(0.35)](/filings/0001193125-26-343424.md) | [0.13](/filings/0001193125-25-263680.md) | not reported | [(0.32)](/filings/0001193125-26-221656.md) | [(0.37)](/filings/0001193125-26-343424.md) |
| Basic EPS | $ per share | [(0.23)](/filings/0000950170-24-121818.md) | not reported | [(0.35)](/filings/0000950170-25-068549.md) | [(0.24)](/filings/0000950170-25-102392.md) | [(0.27)](/filings/0001193125-25-263680.md) | not reported | [(0.36)](/filings/0001193125-26-221656.md) | [(0.35)](/filings/0001193125-26-343424.md) | [0.14](/filings/0001193125-25-263680.md) | not reported | [(0.32)](/filings/0001193125-26-221656.md) | [(0.37)](/filings/0001193125-26-343424.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [58.5](/filings/0000950170-24-121818.md) | [66.4](/filings/0001193125-26-092518.md) | [61.2](/filings/0000950170-25-068549.md) | [51.6](/filings/0000950170-25-102392.md) | [53.1](/filings/0001193125-25-263680.md) | [69.5](/filings/0001193125-26-092518.md) | [58.4](/filings/0001193125-26-221656.md) | [39.3](/filings/0001193125-26-343424.md) | [58.3](/filings/0001193125-25-263680.md) | [112](/filings/0001193125-26-343424.md) | [158](/filings/0001193125-26-221656.md) | [346](/filings/0001193125-26-343424.md) |
| Current assets | $m | [371](/filings/0000950170-23-060682.md) | [347](/filings/0000950170-25-028353.md) | [352](/filings/0000950170-24-055065.md) | [328](/filings/0000950170-24-092274.md) | [301](/filings/0000950170-24-121818.md) | [266](/filings/0001193125-26-092518.md) | [225](/filings/0000950170-25-068549.md) | [190](/filings/0000950170-25-102392.md) | [164](/filings/0001193125-25-263680.md) | [354](/filings/0001193125-26-343424.md) | [392](/filings/0001193125-26-221656.md) | [1,032](/filings/0001193125-26-343424.md) |
| Total assets | $m | [428](/filings/0000950170-23-060682.md) | [403](/filings/0000950170-25-028353.md) | [406](/filings/0000950170-24-055065.md) | [381](/filings/0000950170-24-092274.md) | [352](/filings/0000950170-24-121818.md) | [316](/filings/0001193125-26-092518.md) | [274](/filings/0000950170-25-068549.md) | [238](/filings/0000950170-25-102392.md) | [210](/filings/0001193125-25-263680.md) | [399](/filings/0001193125-26-343424.md) | [436](/filings/0001193125-26-221656.md) | [1,074](/filings/0001193125-26-343424.md) |
| Current liabilities | $m | [43.4](/filings/0000950170-23-060682.md) | [45.9](/filings/0000950170-25-028353.md) | [42.8](/filings/0000950170-24-055065.md) | [43.9](/filings/0000950170-24-092274.md) | [37.6](/filings/0000950170-24-121818.md) | [38.2](/filings/0001193125-26-092518.md) | [35.9](/filings/0000950170-25-068549.md) | [40.0](/filings/0000950170-25-102392.md) | [18.4](/filings/0001193125-25-263680.md) | [21.7](/filings/0001193125-26-343424.md) | [14.3](/filings/0001193125-26-221656.md) | [20.3](/filings/0001193125-26-343424.md) |
| Total liabilities | $m | [152](/filings/0000950170-23-060682.md) | [149](/filings/0000950170-25-028353.md) | [142](/filings/0000950170-24-055065.md) | [134](/filings/0000950170-24-092274.md) | [123](/filings/0000950170-24-121818.md) | [117](/filings/0001193125-26-092518.md) | [108](/filings/0000950170-25-068549.md) | [103](/filings/0000950170-25-102392.md) | [50.1](/filings/0001193125-25-263680.md) | [52.5](/filings/0001193125-26-343424.md) | [44.3](/filings/0001193125-26-221656.md) | [49.3](/filings/0001193125-26-343424.md) |
| Shareholders' equity | $m | [277](/filings/0000950170-24-121818.md) | [253](/filings/0001193125-26-092518.md) | [264](/filings/0001193125-25-263680.md) | [248](/filings/0001193125-25-263680.md) | [229](/filings/0001193125-25-263680.md) | [200](/filings/0001193125-26-343424.md) | [167](/filings/0001193125-26-343424.md) | [135](/filings/0001193125-26-343424.md) | [160](/filings/0001193125-25-263680.md) | [346](/filings/0001193125-26-343424.md) | [392](/filings/0001193125-26-343424.md) | [1,025](/filings/0001193125-26-343424.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(31.1) d](/filings/0000950170-24-121818.md) | [(27.5) d](/filings/0001193125-26-092518.md) | [(37.9)](/filings/0000950170-25-068549.md) | [(23.6) d](/filings/0000950170-25-102392.md) | [(33.4) d](/filings/0001193125-25-263680.md) | [(36.6) d](/filings/0001193125-26-092518.md) | [(41.7)](/filings/0001193125-26-221656.md) | [(36.5) d](/filings/0001193125-26-343424.md) | [(31.0) d](/filings/0001193125-25-263680.md) | [(29.7) d](/filings/0001193125-26-092518.md) | [(44.4)](/filings/0001193125-26-221656.md) | [(38.9) d](/filings/0001193125-26-343424.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-121818.md) | [0.2 d](/filings/0001193125-26-092518.md) | [0.2](/filings/0000950170-25-068549.md) | [0.3 d](/filings/0000950170-25-102392.md) | [0.1 d](/filings/0001193125-25-263680.md) | [0.1 d](/filings/0001193125-26-092518.md) | [0.1](/filings/0001193125-26-221656.md) | [0.6 d](/filings/0001193125-26-343424.md) | [0.2 d](/filings/0001193125-25-263680.md) | [0.2 d](/filings/0001193125-26-092518.md) | [(0.0)](/filings/0001193125-26-221656.md) | [(0.0) d](/filings/0001193125-26-343424.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [87.9](/filings/0000950170-23-060682.md) | [88.2](/filings/0000950170-24-055065.md) | [88.4](/filings/0000950170-24-092274.md) | [97.0](/filings/0000950170-24-121818.md) | [108](/filings/0000950170-25-068549.md) | [108](/filings/0000950170-25-102392.md) | [109](/filings/0001193125-25-263680.md) | [110](/filings/0001193125-26-221656.md) | [111](/filings/0001193125-26-343424.md) | [118](/filings/0001193125-25-263680.md) | [144](/filings/0001193125-26-221656.md) | [150](/filings/0001193125-26-343424.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 168,610,367 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-343424.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.